Cargando…

Increased serum PCSK9 levels are associated with renal function impairment in patients with type 2 diabetes mellitus

PURPOSE: The purpose of this study was to investigate the association between serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and renal function impairment in type 2 diabetes mellitus (T2DM) patients. METHODS: PCSK9 levels were measured in T2DM patients, streptozotocin plus high-f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Zhicai, Liao, Xiangyu, Zhang, Hao, Peng, Juan, Huang, Zhijun, Yi, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228320/ https://www.ncbi.nlm.nih.gov/pubmed/37246753 http://dx.doi.org/10.1080/0886022X.2023.2215880

Ejemplares similares

The predictive utility of circulating PCSK9 levels on diabetes mellitus
por: Peng, Jia, et al.
Publicado: (2021)

Comparison of Serum PCSK9 Levels in Subjects with Normoglycemia, Impaired Fasting Glucose, and Impaired Glucose Tolerance
por: Han, Eugene, et al.
Publicado: (2020)

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
por: Mayne, Janice, et al.
Publicado: (2013)

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
por: Cai, Gaojun, et al.
Publicado: (2018)

The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9
por: Lu, Fengyuan, et al.
Publicado: (2023)

Correlation Between Circulating PCSK9 Levels and Gestational Diabetes Mellitus in a Chinese Population
por: Wu, Yiming, et al.
Publicado: (2022)

PCSK9 Is Increased in Youth With Type 1 Diabetes
por: Levenson, Amy E., et al.
Publicado: (2017)

Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes
por: Wang, Wenting, et al.
Publicado: (2023)

Acute TSH stimulation in vivo does not alter serum PCSK9 levels
por: Gagnon, AnneMarie, et al.
Publicado: (2014)

The association of the PCSK9 rs562556 polymorphism with serum lipids level: a meta-analysis
por: Chuan, Junlan, et al.
Publicado: (2019)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Physical activity to reduce PCSK9 levels
por: Tirandi, Amedeo, et al.
Publicado: (2022)

Effects of increased body weight and short-term weight loss on serum PCSK9 levels – a prospective pilot study
por: Filippatos, Theodosios D, et al.
Publicado: (2017)

Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome
por: Bae, Kwi-Hyun, et al.
Publicado: (2018)

Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer
por: Ito, Masaaki, et al.
Publicado: (2021)

Human Serum PCSK9 Is Elevated at Parturition in Comparison to Nonpregnant Subjects While Serum PCSK9 from Umbilical Cord Blood is Lower Compared to Maternal Blood
por: Peticca, Patricia, et al.
Publicado: (2013)

Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines
por: Zhong, Dong-Xiang, et al.
Publicado: (2021)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Association between the DOCK7, PCSK9 and GALNT2 Gene Polymorphisms and Serum Lipid levels
por: Guo, Tao, et al.
Publicado: (2016)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
por: Handelsman, Yehuda, et al.
Publicado: (2018)

Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus
por: Wang, Mei, et al.
Publicado: (2016)

Vaccine Against PCSK9 Improved Renal Fibrosis by Regulating Fatty Acid β‐Oxidation
por: Wu, Danyu, et al.
Publicado: (2019)

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
por: Toscano, Arianna, et al.
Publicado: (2022)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

Loss-of-function mutation in Pcsk1 increases serum APOA1 level and LCAT activity in mice
por: Khan, Aleksandra Aljakna, et al.
Publicado: (2022)

A Therapeutic Peptide Vaccine Against PCSK9
por: Pan, Yajie, et al.
Publicado: (2017)

Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study
por: Marinelli, Carla, et al.
Publicado: (2022)

SUN-580 PCSK9 and Lp(a): Association Between PCSK9 Level and Larger Apo(a) Isoform Size in African-Americans and Caucasians
por: Byambaa, Enkhmaa, et al.
Publicado: (2020)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
por: Mayne, Janice, et al.
Publicado: (2008)

PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma
por: Fasolato, Silvano, et al.
Publicado: (2020)

Acanthaster planci Inhibits PCSK9 and Lowers Cholesterol Levels in Rats
por: Kamaruddin, Nurjannatul Naim, et al.
Publicado: (2021)

Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study
por: Hsu, Lung-An, et al.
Publicado: (2022)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020)

Autocrine effects of PCSK9 on cardiomyocytes
por: Wolf, Annemarie, et al.
Publicado: (2020)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f5qh5ikesb8uarrhqsdrc88u5n